Ind-Swift Limited (INDSWFTLTD) - Cash Flow Conversion Efficiency

Latest as of March 2025: -0.039x

Based on the latest financial reports, Ind-Swift Limited (INDSWFTLTD) has a cash flow conversion efficiency ratio of -0.039x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs158.56 Million ≈ $1.71 Million USD) by net assets (Rs-4.02 Billion ≈ $-43.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Ind-Swift Limited - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Ind-Swift Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read INDSWFTLTD current and long-term liabilities for a breakdown of total debt and financial obligations.

Ind-Swift Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ind-Swift Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
N/A
Pioneer Lithium Ltd
AU:PLN
N/A
Thai Coating Industrial Public Company Limited
BK:TCOAT
-0.006x
Kwang Jin Ind. Co. Ltd
KQ:026910
0.049x
Bekasi Asri Pemula Tbk
JK:BAPA
-0.003x
Pioneer Embroideries Limited
NSE:PIONEEREMB
0.057x
Venzee Technologies Inc
V:VENZ
-0.012x
Ta Win Holdings Bhd
KLSE:7097
-0.034x

Annual Cash Flow Conversion Efficiency for Ind-Swift Limited (2006–2025)

The table below shows the annual cash flow conversion efficiency of Ind-Swift Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Ind-Swift Limited market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs-4.02 Billion
≈ $-43.51 Million
Rs158.56 Million
≈ $1.71 Million
-0.039x -78.15%
2024-03-31 Rs-6.91 Billion
≈ $-74.71 Million
Rs152.83 Million
≈ $1.65 Million
-0.022x +78.66%
2023-03-31 Rs-7.05 Billion
≈ $-76.21 Million
Rs730.46 Million
≈ $7.90 Million
-0.104x -48.73%
2022-03-31 Rs-7.20 Billion
≈ $-77.90 Million
Rs502.02 Million
≈ $5.43 Million
-0.070x +41.76%
2021-03-31 Rs-6.95 Billion
≈ $-75.18 Million
Rs831.93 Million
≈ $9.00 Million
-0.120x -146.68%
2020-03-31 Rs-7.13 Billion
≈ $-77.12 Million
Rs345.96 Million
≈ $3.74 Million
-0.049x +23.32%
2019-03-31 Rs-6.76 Billion
≈ $-73.14 Million
Rs427.86 Million
≈ $4.63 Million
-0.063x -485.49%
2018-03-31 Rs-6.63 Billion
≈ $-71.72 Million
Rs71.66 Million
≈ $774.98K
-0.011x -486.50%
2017-03-31 Rs-6.16 Billion
≈ $-66.56 Million
Rs-17.21 Million
≈ $-186.10K
0.003x -99.43%
2016-03-31 Rs-2.45 Billion
≈ $-26.54 Million
Rs-1.19 Billion
≈ $-12.92 Million
0.487x +122.46%
2015-03-31 Rs-395.00 Million
≈ $-4.27 Million
Rs855.75 Million
≈ $9.25 Million
-2.166x -328.56%
2014-03-31 Rs1.08 Billion
≈ $11.72 Million
Rs1.03 Billion
≈ $11.11 Million
0.948x +240.79%
2013-03-31 Rs2.17 Billion
≈ $23.50 Million
Rs-1.46 Billion
≈ $-15.82 Million
-0.673x -470.93%
2011-03-31 Rs3.30 Billion
≈ $35.67 Million
Rs598.64 Million
≈ $6.47 Million
0.182x +9122.60%
2010-03-31 Rs2.80 Billion
≈ $30.26 Million
Rs-5.63 Million
≈ $-60.88K
-0.002x -100.95%
2009-03-31 Rs2.42 Billion
≈ $26.12 Million
Rs509.22 Million
≈ $5.51 Million
0.211x +76.03%
2008-03-31 Rs1.78 Billion
≈ $19.27 Million
Rs213.43 Million
≈ $2.31 Million
0.120x +316.53%
2007-03-31 Rs1.49 Billion
≈ $16.09 Million
Rs-82.28 Million
≈ $-889.78K
-0.055x -206.94%
2006-03-31 Rs1.30 Billion
≈ $14.03 Million
Rs67.09 Million
≈ $725.56K
0.052x --

About Ind-Swift Limited

NSE:INDSWFTLTD India
Market Cap
$9.23 Million
Rs853.64 Million INR
Market Cap Rank
#27077 Global
#1523 in India
Share Price
Rs15.76
Change (1 day)
+6.13%
52-Week Range
Rs12.47 - Rs18.91
All Time High
Rs33.25
About

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin… Read more